公开(公告)号：US20170095462A1

公开(公告)日：2017-04-06

申请号：US15387537

申请日：2016-12-21

Applicant: InterMune, Inc.

Inventor： Lawrence M. Blatt ,  Scott D. Seiwert ,  Leonid D. Beigelman ,  Ramachandran Radhakrishnan ,  Karl Kossen ,  Vladimir Serebryany

IPC: A61K31/4412 ,  A61K31/444 ,  A61K31/44

CPC classification number: A61K31/4412 ,  A61K31/44 ,  A61K31/444 ,  A61K31/45 ,  A61K31/4704 ,  A61K31/7052 ,  A61K47/56 ,  A61K47/58 ,  C07D213/16 ,  C07D213/26 ,  C07D213/63 ,  C07D213/64 ,  C07D213/69 ,  C07D215/227 ,  C07H15/26 ,  C07K1/1077 ,  C08F289/00 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/475

Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

公开(公告)号：US09527816B2

公开(公告)日：2016-12-27

申请号：US14263787

申请日：2014-04-28

Applicant: InterMune, Inc.

Inventor： Lawrence M. Blatt ,  Scott D. Seiwert ,  Leonid D. Beigelman ,  Ramachandran Radhakrishnan ,  Karl Kossen ,  Vladimir Serebryany

IPC: A61K31/44 ,  A61K31/4412 ,  C07D213/26 ,  C07D213/63 ,  C07D213/16 ,  C07D213/64 ,  C07D215/227 ,  A61K31/4704 ,  A61K31/7052 ,  A61K31/45 ,  C07D213/69 ,  C07H15/26

CPC classification number: A61K31/4412 ,  A61K31/44 ,  A61K31/444 ,  A61K31/45 ,  A61K31/4704 ,  A61K31/7052 ,  A61K47/56 ,  A61K47/58 ,  C07D213/16 ,  C07D213/26 ,  C07D213/63 ,  C07D213/64 ,  C07D213/69 ,  C07D215/227 ,  C07H15/26 ,  C07K1/1077 ,  C08F289/00 ,  Y02A50/401 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/475

Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

公开(公告)号：US20150266899A1

公开(公告)日：2015-09-24

申请号：US14432881

申请日：2013-10-01

Applicant: INTERMUNE, INC.

Inventor： Brad Owen Buckman ,  John Beamond Nicholas ,  Johnnie Y. Ramphal ,  Kumaraswamy Emayan ,  Scott D. Seiwert

IPC: C07D513/04 ,  C07D213/64 ,  C07D498/04 ,  C07D221/04 ,  C07D217/24 ,  C07D471/04 ,  C07D495/04 ,  C07D401/04

CPC classification number: A61K31/437 ,  A61K9/007 ,  C07D211/86 ,  C07D213/64 ,  C07D217/24 ,  C07D221/04 ,  C07D223/10 ,  C07D295/125 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Abstract translation: 公开了吡啶酮化合物，这些化合物的制备方法和治疗纤维化疾病的方法。

公开(公告)号：US20140235637A1

公开(公告)日：2014-08-21

申请号：US14263822

申请日：2014-04-28

Applicant: InterMune, Inc.

Inventor： Karl Kossen ,  Scott D. Seiwert ,  Vladimir Serebryany ,  Donald Ruhrmund ,  Leonid D. Beigelman ,  Luca Francesco Mario Raveglia ,  Stefania Vallese ,  Ivana Bianchi ,  Tao Hu

IPC: C07D213/64 ,  C07D417/04 ,  C07D409/04 ,  C07D405/04 ,  C07D213/85

CPC classification number: C07D213/63 ,  C07D213/22 ,  C07D213/64 ,  C07D213/69 ,  C07D213/71 ,  C07D213/85 ,  C07D237/14 ,  C07D239/36 ,  C07D239/54 ,  C07D241/18 ,  C07D251/10 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

Abstract translation: 公开了用于治疗炎症和纤维化疾病的化合物和方法，包括用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物表现出低的抑制p38MAPK的能力; 并且其中所述接触以对所述化合物抑制p38MAPK的抑制浓度低的SAPK调节浓度进行。 还公开了吡非尼酮的衍生物和类似物，其可用于调节应激活化蛋白激酶（SAPK）系统。

公开(公告)号：US20140213538A1

公开(公告)日：2014-07-31

申请号：US14156316

申请日：2014-01-15

Applicant: InterMune, Inc.

Inventor： Brad Owen Buckman ,  John Beamond Nicholas ,  Kumaraswamy Emayan ,  Scott D. Seiwert ,  Shendong Yuan

IPC: C07D513/04 ,  C07D275/03 ,  C07D413/10 ,  C07H15/26 ,  C07D495/04 ,  C07D491/048 ,  A61K9/00 ,  C07D261/14 ,  C07D487/04

CPC classification number: C07D513/04 ,  C07D261/14 ,  C07D275/03 ,  C07D401/12 ,  C07D405/10 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04

Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Abstract translation: 提供化合物，制备这些化合物的方法，药物组合物和包含这些化合物的药物，以及使用这些化合物治疗，预防或诊断与一种或多种溶血磷脂酸受体相关的疾病，病症或病症的方法。

公开(公告)号：US10898474B2

公开(公告)日：2021-01-26

申请号：US16454623

申请日：2019-06-27

Applicant: INTERMUNE, INC.

Inventor： Brad Owen Buckman ,  John Beamond Nicholas ,  Johnnie Y. Ramphal ,  Kumaraswamy Emayan ,  Scott D. Seiwert

IPC: C07D213/02 ,  A61K31/437 ,  C07D513/04 ,  C07D495/04 ,  C07D211/86 ,  C07D401/04 ,  C07D221/04 ,  C07D471/04 ,  C07D498/04 ,  C07D295/125 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D223/10 ,  C07D405/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D213/64 ,  C07D217/24 ,  A61K9/00

Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

公开(公告)号：USRE47142E1

公开(公告)日：2018-11-27

申请号：US14534450

申请日：2014-11-06

Applicant: InterMune, Inc.

Inventor： Karl Kossen ,  Scott D. Seiwert ,  Vladimir Serebryany ,  Donald Ruhrmund ,  Leonid Beigelman ,  Luca Francesco Mario Raveglia ,  Stefania Vallese ,  Ivana Bianchi ,  Tao Hu

IPC: C07D213/63 ,  C07D213/85 ,  C07D405/14 ,  C07D239/36 ,  C07D213/69 ,  C07D251/10 ,  C07D409/04 ,  C07D239/54 ,  C07D413/14 ,  C07D237/14 ,  C07D213/22 ,  C07D213/71 ,  C07D241/18 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D213/64 ,  C07D417/14 ,  C07D401/04

Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.Mederski et al., Tetrahedron (1999), 55(44), 12757-12770.*Azuma et al., “A placebo control and double blind phase II clinical study of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan”, Am J Respir Crit Care Med., 165:A729 (2002).Badger, et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function”, J. Pharmacol. Exp. Ther. 279:1453-61 (1996).

公开(公告)号：US20170121345A1

公开(公告)日：2017-05-04

申请号：US15128061

申请日：2015-03-31

Applicant: InterMune, Inc.

Inventor： Johnnie Y. Ramphal ,  Brad Owen Buckman ,  Kumaraswamy Emayan ,  John Beamond Nicholas ,  Scott D. Seiwert

IPC: C07D498/04 ,  C07D213/64 ,  C07D221/04 ,  C07D471/04 ,  C07D513/04 ,  C07D487/04 ,  C07D211/76 ,  C07D401/12 ,  C07D401/04 ,  C07D417/10 ,  C07D405/02 ,  C07D413/02 ,  C07D495/04 ,  C07D209/34

CPC classification number: C07D498/04 ,  C07C25/18 ,  C07C225/20 ,  C07D209/34 ,  C07D211/76 ,  C07D213/64 ,  C07D213/69 ,  C07D213/74 ,  C07D213/75 ,  C07D221/04 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/02 ,  C07D405/04 ,  C07D405/14 ,  C07D413/02 ,  C07D413/04 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

公开(公告)号：US20140200215A1

公开(公告)日：2014-07-17

申请号：US13795605

申请日：2013-03-12

Applicant: INTERMUNE, INC.

Inventor： Brad Owen Buckman ,  John Beamond Nicholas ,  Kumaraswamy Emayan ,  Scott D. Seiwert

IPC: C07D261/14 ,  C07D487/04 ,  C07D417/10 ,  C07D495/04 ,  C07D275/03 ,  C07D413/10

CPC classification number: C07D261/14 ,  C07D275/03 ,  C07D405/10 ,  C07D413/10 ,  C07D417/10 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04 ,  C07D519/00

Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

公开(公告)号：US20130102597A1

公开(公告)日：2013-04-25

申请号：US13652247

申请日：2012-10-15

Applicant: INTERMUNE, INC.

Inventor： Karl Kossen ,  Scott D. Seiwert ,  Vladimir Serebryany ,  Donald Ruhrmund ,  Leonid Beigelman ,  Luca Francesco Mario Raveglia ,  Stefania Vallese ,  Ivana Bianchi ,  Tao Hu

IPC: C07D213/63 ,  C07D213/85 ,  C07D239/36 ,  C07D251/10 ,  C07D239/54 ,  C07D409/04 ,  C07D213/69 ,  C07D405/04 ,  C07D417/04 ,  C07D405/14 ,  C07D413/04 ,  C07D471/04 ,  C07D413/14 ,  C07D417/14 ,  C07D401/04

CPC classification number: C07D213/63 ,  C07D213/22 ,  C07D213/64 ,  C07D213/69 ,  C07D213/71 ,  C07D213/85 ,  C07D237/14 ,  C07D239/36 ,  C07D239/54 ,  C07D241/18 ,  C07D251/10 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.